• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Restasis Contract Sales Force

Does anyone actually see the Green team lasting through Q2? Or will they cut Blue and keep Green to save money?

We certainly don't need three Vuity reps, two of whom have Restasis which is dying really quickly to generics.
 








Similar threads